§ Claim under review · Mixed
"Niacinamide is a multifunctional cosmetic ingredient that, at commonly used concentrations (around 2–5%), supports multiple skin concerns including fine lines, uneven tone, excess sebum, skin barrier function, acne-prone skin, and hyperpigmentation, while maintaining a favorable safety profile when properly formulated"
Verdict
Mostly accurate
Confidence
MediumSummary
This post about niacinamide is mostly accurate. Real randomised trials support each benefit it lists, and the safety record is solid: an expert panel review found niacinamide safe as used in cosmetics, with no stinging up to 10 percent and no irritation in use tests up to 5 percent. The main gap is concentration. Most of the trials behind the fine lines, acne and pigmentation results used 4 or 5 percent, and only the oil-reduction finding was measured at 2 percent, so the post's single "2 to 5 percent" band spreads the evidence more evenly than the studies do. The barrier-strengthening item rests on a described biological mechanism rather than on a trial found in this check. Some of the underlying research, particularly on wrinkles and oil production, was carried out by a cosmetics manufacturer, which the post does not mention, though the acne and pigmentation results have been repeated by independent academic teams. The post also credits a publication whose own publisher describes it as not a scientific journal, and that specific article could not be retrieved. General information only, not medical or dermatological advice.
The readings
key figures from the evidenceniacinamide conc in photoaging split-face trial
niacinamide vs 4% hydroquinone in melasma trial
max conc with no stinging in CIR safety testing
Why this verdict
Evidence
Randomised clinical evidence exists for topical niacinamide on each endpoint named, but at different concentrations and with different strength.
Fine lines and tone: in a 12 week double blind, placebo controlled, split face study of 50 white women aged 40 to 60 with facial photoaging, 5% niacinamide in a moisturiser gave significant improvements versus the same moisturiser without it in fine lines and wrinkles, hyperpigmented spots, texture, red blotchiness and yellowing. The endpoints are appearance measures and the work was done at Procter and Gamble.
Hyperpigmentation: a double blind split face trial in 27 melasma patients compared 4% niacinamide with 4% hydroquinone over 8 weeks; colorimetric assessment showed no statistical difference between the two sides, while hydroquinone's lightening was visible earlier. A separate 9 week randomised, double blind, placebo controlled study tested 4% niacinamide and 0.05% desonide for axillary hyperpigmentation. A further randomised vehicle controlled trial of 4% niacinamide plus 2% N-acetyl glucosamine reported significantly lower spot area fraction at weeks 6 and 8.
Acne: a randomised double blind trial allocated 80 patients with moderate inflammatory facial acne to 4% nicotinamide or 1% clindamycin gel twice daily; both improved acne, with nicotinamide performing better in oily skin and clindamycin better in non-oily skin. Another double blind randomised trial compared 5% nicotinamide gel with 2% clindamycin gel in mild to moderate acne.
Sebum: two trials of a 2% niacinamide moisturiser, 100 Japanese subjects (double blind, placebo controlled, parallel groups) and 50 US subjects, reported significantly lowered sebum excretion rate versus placebo at 2 and 4 weeks.
Safety: the CIR Expert Panel concluded niacinamide and niacin are safe as used in cosmetics. Clinical testing produced no stinging up to 10%, no irritation in use tests up to 5%, and no irritancy in a 21 day cumulative irritation test up to 5%. The Panel recorded that these ingredients are not significant skin irritants, sensitisers or photosensitisers, that some formulations were marginal to slight ocular irritants while others were not, and that niacinamide is not carcinogenic alone though it can modulate tumour induction by certain established carcinogens at doses high relative to cosmetic use concentrations. At the time of that report, reported use concentrations ran from 0.0001% in night preparations to 3% in body and hand creams, lotions, powders and sprays.
The cited source: the publisher of the CosmEthically ACTIVE Journal states on its own pages that the publication is not a scientific journal and is intended for a wider audience, and that the same association runs the CosmEthically ACTIVE certification. The specific article cited in the post (Berglez P, Cos ACTIVE J. 2025;3:22-29) was not retrievable.
Findings
✓ What's accurate 7
- Topical niacinamide has randomised clinical evidence across each endpoint named in the claim, from separate trials rather than one study.
- At 5%, in 50 white women aged 40 to 60 over 12 weeks, split face against the same moisturiser base, niacinamide significantly improved the appearance of fine lines and wrinkles, hyperpigmented spots, texture, red blotchiness and yellowing.
- At 4%, in 80 patients with moderate inflammatory facial acne, nicotinamide gel improved acne over 8 weeks, and did so more than 1% clindamycin in the oily-skin subgroup.
- At 4%, in 27 melasma patients, niacinamide was not statistically different from 4% hydroquinone on colorimetric assessment over 8 weeks.
- At 2%, sebum excretion rate fell significantly versus placebo after 2 and 4 weeks in a 100-subject Japanese trial and a 50-subject US trial.
- Tolerability is well documented. The CIR Expert Panel found no stinging up to 10%, no irritation in use tests up to 5%, and concluded niacinamide is safe as used in cosmetics, not a significant irritant, sensitiser or photosensitiser.
- The claim's own qualifier, that results depend on formulation and that a study concentration does not transfer automatically to a product claim, matches how the evidence behaves.
≈ What's misleading 5
- The concentration band is stated as "around 2 to 5%" for the whole list, but the evidence is not spread evenly across it. Fine lines and overall tone rest on 5% work; acne and pigmentation on 4%; only the sebum finding was measured at 2%. A reader could take 2% as sufficient for all six concerns, which the trials do not show.
- "Supports skin barrier function" is the weakest item in the list. The mechanism, ceramide synthesis and reduced water loss, is widely described, but no barrier trial at 2 to 5% was retrieved in this investigation to place beside the acne, pigment and sebum trials. A described mechanism is context, not a measured effect.
- Funding is not stated in the post. The photoaging and sebum evidence, which carries the fine lines, tone and sebum items, comes from Procter and Gamble research. The acne and pigmentation findings have independent academic replication; the appearance and sebum findings, as located here, do not.
- The trials measure appearance and instrument readings over 4 to 12 weeks in specific groups, for example women aged 40 to 60 in the photoaging study. The claim is written as a general property of the ingredient for all users.
- The post presents its source as a published journal article, and the publisher's own pages describe the CosmEthically ACTIVE Journal as not a scientific journal, aimed at a wider audience. The "Approved by Modern CosmEthics" label refers to a certification run by the same association that publishes the journal.
? What's uncertain 5
- No systematic review or meta-analysis of topical niacinamide was located within this investigation, so the pooled size and durability of the effects across trials is not established here.
- Barrier function at 2 to 5% could not be supported with a retrieved clinical trial, only with mechanistic and review literature.
- The cited article, Berglez P, Cos ACTIVE J. 2025;3:22-29, could not be retrieved, so what it actually argues, and whether the post represents it accurately, is unverified. The caption's "2026" and the citation's "2025" do not match.
- The CIR maximum reported use concentration of 3% dates from 2005, and current market concentrations commonly exceed that, so the safety record cited does not speak to today's highest-strength products with the same currency.
- The claim's safety element names no jurisdiction. Rules vary by country; this claim didn't name one.
Sources
9 of 9 linked to recordsCIR Expert Panel, Final Report of the Safety Assessment of Niacinamide and Niacin, Int J Toxicol 2005
Bissett DL et al., Topical niacinamide reduces yellowing, wrinkling, red blotchiness and hyperpigmented spots in aging facial skin, Int J Cosmet Sci 2004 (5%, split-face, n=50)
Khodaeiani E et al., Topical 4% nicotinamide vs 1% clindamycin in moderate inflammatory acne vulgaris, Int J Dermatol 2013 (RCT, n=80)
Navarrete-Solís J et al., Niacinamide 4% versus hydroquinone 4% in melasma, Dermatol Res Pract 2011 (split-face RCT, n=27)
Castanedo-Cazares JP et al., Topical niacinamide 4% and desonide 0.05% for axillary hyperpigmentation, randomized, double-blind, placebo-controlled, 9 weeks
Draelos ZD et al., The effect of 2% niacinamide on facial sebum production, J Cosmet Laser Ther 2006 (two trials, Japan n=100, USA n=50)
Marques C et al., Mechanistic insights into the multiple functions of niacinamide, review 2024
CosmEthically ACTIVE Journal publisher pages (the cited source's own description)
Bissett DL et al., N-undecyl-10-enoyl-L-phenylalanine with niacinamide, J Cosmet Dermatol 2009 (5% niacinamide arms, funded by Procter and Gamble Beauty)